Simulations Plus, Inc. logo SLP - Simulations Plus, Inc.

Inactive Ticker SLP is not actively trading. Quotes and analytics may be stale.
Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY 0
BUY 4
HOLD 5
SELL 0
STRONG
SELL 0
| PRICE TARGET: $18.50 DETAILS
HIGH: $18.50
LOW: $18.50
MEDIAN: $18.50
CONSENSUS: $18.50
UPSIDE: 0.00%

Stock News

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology (QSP), within an active therapeutic development program. The collaboration will evaluate how AI-enabled.

Oct 08, 2026 05:15 AM • businesswire.com
Simulations Plus Announces Completion of Acquisition by Altaris

Simulations Plus Announces Completion of Acquisition by Altaris

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition by affiliates of Altaris, LLC ("Altaris"), an investment firm focused exclusively on the healthcare industry.The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations.

Oct 06, 2026 05:15 AM • businesswire.com
Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration's (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology.

Sep 17, 2026 01:45 PM • businesswire.com
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

SAN DIEGO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses and whether they may recover those losses under federal securities laws. On April 3, 2025, Simulations Plus reported its financial results for the second quarter of fiscal 2025 and maintained full-year revenue guidance of $90 million to $93 million.

Aug 20, 2026 06:28 AM • globenewswire.com (Hide legal announcements)
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

SAN DIEGO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses and whether they may recover those losses under federal securities laws. On April 3, 2025, Simulations Plus reported its financial results for the second quarter of fiscal 2025 and maintained full-year revenue guidance of $90 million to $93 million.

Aug 20, 2026 06:28 AM • globenewswire.com (Hide legal announcements)
Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company's previously announced acquisition by Altaris, LLC. The expiration of the HSR waiting period satisfies one of the regulatory cond.

Aug 13, 2026 01:00 PM • businesswire.com
Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP

Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Simulations Plus, Inc. (NasdaqGS: SLP) to affiliates of Altaris, LLC. Under the terms of the proposed transaction, shareholders of Simulations will receive $18.50 in cash for each share of Simulations that they own. KSF is seeking to determine whether this consideration and the process that led to i.

Jul 30, 2026 08:05 AM • businesswire.com (Hide legal announcements)
Simulation Plus, Inc. Securities Fraud Investigation - Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws

Simulation Plus, Inc. Securities Fraud Investigation - Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws

San Diego, California--(Newsfile Corp. - July 29, 2026) - Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violated securities laws or breached fiduciary duties owed to shareholders The investigation concerns whether Simulation Plus made materially false or misleading statements or omitted material information regarding its financial reporting, internal controls, and business outlook. Investors who purchased Simulation Plus securities and suffered losses may have legal rights.

Jul 29, 2026 01:25 PM • newsfilecorp.com

Price Targets